Folvidon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folvidon

Quick Facts

Property Description
Active ingredient Folic Acid (Vitamin B9)
Form Oral Tablet
Pharmacological class Hematopoietic agent (Antianemic)
General purpose Supports essential blood cell formation and DNA synthesis
Origin Synthetic

Folvidon: Identity, Composition, and Role

Folvidon is a pharmaceutical preparation delivered as an oral tablet that contains the single active substance, Folic Acid. This compound is chemically defined as Pteroylglutamic Acid and is universally known as Vitamin B9. This preparation is recognized as a reliable, monocomponent therapeutic agent that provides a stable source of this essential nutrient. The synthetic Folic Acid used in this product is favored in pharmaceutical preparations over natural dietary forms, known as folates, due to its superior stability and predictable absorption.

Classification: Water-Soluble Vitamin and Hematopoietic Agent

Folvidon is classified both as a Water-soluble Vitamin and, based on its confirmed biological activity, a Hematopoietic agent or Antianemic preparation. It is clinically recognized for its necessity in promoting the formation and efficient maturation of healthy blood cells. As an essential nutrient, the body cannot synthesize Vitamin B9 internally, which places this preparation within the vital Vitamin B complex and underscores the importance of external supplementation.

General Purpose of Folvidon (Vitamin B9)

The general purpose of Folvidon is to supply the critical co-factor needed for fundamental metabolic processes, specifically supporting the proper creation and replication of cellular DNA and RNA. By supporting DNA synthesis and rapid cell division, the preparation aids tissues with high turnover rates. This function is vital for promoting stable red blood cell production and overall cellular health.

What side effects are possible with Folvidon?

Possible side effects and safety information

The safety profile for Folvidon (Folic Acid) outlines officially documented adverse reactions, which are generally categorized as rare or having an unknown frequency. These effects are reported across several system-organ classes, as defined in regulatory documents.

Documented Adverse Reactions

Adverse reactions involving the Gastrointestinal System (e.g., nausea, anorexia, abdominal distension, and flatulence) are documented but are typically categorized as rare. Reactions affecting the Skin and Immune System are also reported, ranging from rare occurrences of reddened skin (erythema) and rash to potentially life-threatening reactions. The most severe of these, an Anaphylactic Reaction (including shock), is listed as a serious adverse reaction with a frequency classified as Not Known.

Critical Safety Restrictions

Regulatory safety information places primary emphasis on a critical restriction: the use of Folic Acid can mask the hematological signs of untreated Vitamin B12 deficiency (Pernicious Anemia). This masking effect allows irreversible neurological damage (Subacute Combined Degeneration of the Spinal Cord) to progress undetected. Consequently, the preparation is not indicated for use alone in managing B12 deficiency.

Exposure-Related Patterns

For high doses administered over a prolonged duration, the official labeling documents the potential for adverse effects involving the Nervous System and Psychiatric Disorders. These include altered sleep patterns, confusion, irritability, and difficulty concentrating. Safety warnings also exist for patients taking certain anticonvulsants, as Folic Acid may potentially increase the incidence of seizures in these individuals.

Overdose and Emergency Response

Regulatory documents state that Folvidon (Folic Acid) has a low acute toxicity profile, and ingestion of amounts significantly exceeding the prescribed dose is generally considered unlikely to cause immediate, acute harm. No specific antidote is known or required for an acute overdose; management is therefore limited to symptomatic and supportive treatment.

When to Seek Urgent Medical Help

Emergency medical care is explicitly required immediately if any signs of a severe allergic reaction or hypersensitivity occur. This includes manifestations such as hives, swelling of the face, lips, tongue, or throat, or difficulty breathing, as these symptoms can indicate anaphylactic shock. Contact emergency services immediately if these regulator-documented severe reactions appear.

Chronic Risks and Documented Manifestations

Regulatory authorities caution that prolonged, excessive intake carries the critical risk of masking the hematological signs of an underlying Vitamin B12 deficiency (pernicious anemia). This concealment can allow for the progression of irreversible neurological damage (e.g., in the spinal cord). Furthermore, chronic over-intake has been associated with non-acute manifestations, including specific Central Nervous System effects such as irritability, confusion, altered sleep patterns, and gastrointestinal disturbances like nausea and flatulence.

Therapeutic Uses of Folvidon

Easing Severe Nausea and Persistent Vomiting

Folvidon is primarily used for symptomatic relief in conditions characterized by periods of heightened symptoms, specifically for managing the nausea and vomiting of pregnancy (NVP) when initial supportive efforts have not been sufficient. The medication is applied to address symptoms related to physical discomfort and heightened physiological activity, helping to relieve constant and intense feelings of sick stomach and reduce the frequency of vomiting episodes. This approach is commonly used across conditions presenting with acute episodes, where supportive symptom management is appropriate.

The medication is relevant for easing challenging symptoms, such as persistent nausea and recurrent vomiting. This provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Severe Sickness The medication may be part of symptomatic management when symptoms create noticeable physiological strain.


Nutritional Assistance for Comfort and Stability

The medication is applied across domains where additional symptomatic support is needed. This is relevant for easing symptoms related to systemic imbalance. This is applied in scenarios where additional management of discomfort is required, as the support may assist with maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility to Use Folvidon (Folic Acid)

The official regulatory profile for Folvidon defines strict eligibility criteria based on the active ingredient, Folic Acid. These criteria establish who is permitted to use the medicine and under what conditions its use is prohibited.

Contraindications and Restrictions

Folvidon is contraindicated in patients with a known hypersensitivity to the medicine or its components. Crucially, the medicine must not be used in patients with undiagnosed or untreated pernicious anemia or other megaloblastic anemias caused by Vitamin B12 deficiency. Regulatory agencies mandate that the underlying cause of anemia must be confirmed as folate deficiency before treatment, as Folic Acid can mask the blood-related symptoms of B12 deficiency while allowing irreversible neurological damage to advance.

Approved Populations

Use of Folvidon is established and permitted for the treatment of confirmed folate deficiency in adults, the pediatric population (infants and children), and older adults.

Additionally, use is permitted and recommended during pregnancy and lactation for the prevention of neural tube defects and the treatment of maternal deficiency. No specific absolute restrictions are generally documented for use in patients with severe renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Folvidon (Folic Acid) is defined by officially documented reports of therapeutic antagonism and altered drug exposure, strictly as stated in government regulatory sources.

Documented Pharmacological Antagonism

Folic Acid is documented to engage in pharmacological antagonism with several drug classes. Co-administration may reduce the therapeutic effects of antifolate agents such as Methotrexate and Pyrimethamine. Furthermore, Folic Acid has been officially reported to antagonize the action of certain anticonvulsant medicines, including Phenytoin and Primidone, which may be associated with decreased serum levels of the anticonvulsant. In some documented cases, Folic Acid has been reported to increase the incidence of seizures in patients stabilized on Primidone.

Exposure Alteration and Administration Constraints

Interactions involving altered exposure or absorption are also documented. Co-administration with Antacids (specifically those containing Aluminium or Magnesium) may interfere with the absorption of Folic Acid, potentially leading to reduced exposure. Regulatory guidance therefore indicates that a mandatory separation of administration time is required for these combinations. Additionally, co-administration with the antibiotic Tetracycline is documented to cause false low serum and red cell folate levels, which is an interference with diagnostic assays.

Mechanism of Action

Folvidon's mechanism centers on supplying the essential metabolic precursor, Folic Acid, required for the body's fundamental processes of cell division and DNA synthesis. This action is required by tissues that experience high cellular turnover.


Enzyme-Mediated Activation and Co-factor Supply

The molecule is first converted into its active form, Tetrahydrofolate (THF), by the enzyme Dihydrofolate Reductase (DHFR). This activated molecule functions as an essential co-factor within one-carbon metabolism, acting as a carrier and donor of necessary chemical groups. This provides a steady supply of the required metabolic resources needed to fuel downstream biosynthetic reactions.


Support for DNA Synthesis and Cellular Proliferation

The active folate co-factors are vital for synthesizing the building blocks of DNA, specifically by enabling the enzyme Thymidylate Synthase to produce deoxythymidylate monophosphate (dTMP) and by participating in purine synthesis. This mechanism directly supports cell division, which is a necessary condition for biological function in tissues like the blood-forming system.


Enabling Hematopoietic Maturation

By addressing the insufficient availability of DNA precursors, the mechanism facilitates proliferation and maturation of blood cell precursors in the bone marrow. This physiological effect influences the structural formation resulting from stalled DNA production, resulting in normal cell size and morphology in the red blood cell lineage.

Dosage and Administration Information

Folvidon (Folic Acid) is primarily administered via the oral route using the tablet formulation, with parenteral routes (IV, IM, SC) reserved for specific clinical needs such as severe illness or confirmed malabsorption where oral intake is not feasible. The use protocol adheres to a two-phase daily pattern: an initial therapeutic dose followed by a long-term maintenance dose.

Administration Feature Official Guideline
Primary Route Oral administration.
Frequency Once daily for both phases.
Initial Dose Up to 1 mg once daily.
Maintenance Dose 0.4 mg once daily for most adults.
Meal Timing The tablet may be taken with or without food.

The therapeutic regimen is governed by a high-level procedural precondition: administration of doses exceeding 0.1 mg must not be initiated unless a coexisting B12 deficiency has been formally excluded or is being adequately managed. This restriction ensures the proper setting for treatment.

The initial course continues daily until the patient's hematological profile normalizes, a period that often lasts up to approximately four months. Following this resolution, the regimen transitions to the established maintenance level for long-term support in cases where the underlying deficiency is chronic. Population-specific adjustments are established, such as an elevated maintenance dose of 0.8 mg once daily specifically for pregnant or lactating women.

Recent Clinical Evidence

Evidence for Use in Preventing Neural Tube Defects (NTDs)

Research is largely based on well-established Randomized Controlled Trials (RCTs) and Systematic Reviews that investigated Folic Acid use during the periconception period. Studies were applied in women of childbearing age, and research monitored outcomes related to the incidence of NTDs, such as spina bifida. Findings consistently reported patterns observed in the studies related to consumption and the occurrence of NTDs. However, existing evidence provides limited insight into how these outcomes apply to populations already subject to mandatory food fortification.

Evidence for Use in Managing Folate Deficiency

Evidence for the hematopoietic role of Folic Acid is underpinned by numerous clinical observations and trials. These studies were applied in populations diagnosed with deficiency, and research focused on key hematological parameters, such as Red Blood Cell count and size. Studies monitored changes in these parameters following administration. Regulatory summaries note that high-dose administration presents a risk pattern where the blood changes of a co-existing Vitamin B12 deficiency can be masked, which remains an area of uncertainty.

Evidence on Cardiovascular Risk Factors

Research has examined Folic Acid for its influence on cardiovascular risk using large, long-term RCTs and Meta-Analyses. Studies monitored the incidence of stroke events and the biomarker Homocysteine. Findings regarding stroke incidence were mixed. Research exploring whether the measured effects were influenced reported patterns varying across studies, often associated with the participants’ baseline Vitamin B12 status and the level of regional food fortification.

What Remains Uncertain about the Folvidon Evidence Base

Key limitations noted in scientific literature include the influence of existing food fortification on efficacy, making results highly context-dependent. Specific dosing evidence for subgroups with severe renal or hepatic impairment remains insufficient. The primary risk pattern of masking Vitamin B12 deficiency means the need for monitoring remains a major area of uncertainty and differentiation in clinical practice.

Key Studies & References

  1. Recommendations for the Use of Folic Acid to Reduce the Number of Cases of Spina Bifida and Other Neural Tube Defects (US Public Health Service)
  2. FOLIC ACID TABLETS, USP - DailyMed (Prescribing Information and Indications)

Frequently Asked Questions (FAQ)

Common questions about Folvidon (FAQ)

Q: Is Folvidon considered a stimulant, or does it work differently?

Folvidon, whose active ingredient is Folic Acid, is officially classified as a water-soluble vitamin and a hematopoietic agent (antianemic). Regulatory sources describe its function as primarily supporting DNA synthesis and red blood cell production. It is not classified as a central nervous system stimulant.


Q: Is it common to feel tired or drowsy after taking Folvidon?

Official product information states that fatigue is a known symptom of the folate deficiency the medicine is intended to correct. However, nervous system effects such as confusion or altered sleep patterns have been reported, primarily with the prolonged use of high doses. Drowsiness itself is not a commonly listed side effect.


Q: Can Folvidon be taken by people with kidney or liver issues?

Official documentation indicates that specific dose adjustments for Folic Acid are generally undefined in patients with impaired kidney or liver function. High-dose Folic Acid has not been strongly associated with direct liver injury in clinical reports. Regulatory documents recommend that patients with severe organ impairment consult a healthcare professional regarding their treatment.


Q: Is Folvidon known to cause dry mouth or changes in appetite?

According to official product information, a loss of appetite, known as anorexia, is a documented adverse effect of Folic Acid. However, dry mouth is not consistently listed among the commonly reported side effects in regulatory documents.


Q: What are the most commonly reported side effects in the clinical trials for Folvidon?

Documented gastrointestinal disturbances associated with Folvidon include flatulence, nausea, abdominal distension, and a general loss of appetite. Official information often categorizes these effects as rare or having an unknown frequency.


Q: Can Folvidon cause changes in mood or anxiety levels?

Official product information reports that nervous system effects, such as irritability, excitement, confusion, and mental depression, have been documented. These effects are reported primarily with prolonged high-dose administration. Anxiety itself is not explicitly listed, but the noted effects relate to changes in mood.


Q: What should I know about driving or operating machinery while using Folvidon?

Nervous system effects reported with high-dose use, such as impaired judgment, confusion, and difficulty concentrating, may potentially affect a person's ability to drive or operate machinery. Awareness of these effects is important for patients, as documented in the official safety information.


Q: Does the time of day I take Folvidon matter for its effectiveness?

Folvidon is prescribed as a once-daily medicine and may be taken with or without food. Because altered sleep patterns are a documented side effect, patients may wish to discuss the ideal administration time with a healthcare professional.


Q: Is there a weight gain or weight loss side effect commonly associated with Folvidon?

Loss of appetite (anorexia) is a documented adverse effect of Folvidon. However, a direct change in weight (either weight gain or weight loss) is not consistently listed as a common or primary side effect in official regulatory profiles.


Q: Are there any specific supplements or vitamins that should be avoided with Folvidon?

Official sources advise consulting a healthcare professional before taking supplements containing ingredients like zinc or green tea, as they may be involved in a potential interaction. This information supplements the core warning regarding Vitamin B12 deficiency.


Q: How quickly should I expect to notice anything after starting Folvidon?

Official pharmacology reports indicate that the onset of action for Folic Acid after oral administration is typically within approximately 30 minutes to one hour. This refers to the time needed for the medicine to enter the bloodstream and begin its action.


Q: Does Folvidon build up in the body over time?

Folic Acid is a water-soluble vitamin, meaning it is typically excreted from the body. However, studies have examined high daily doses, where the body’s ability to process the acid is saturated, which can lead to unmetabolized folic acid appearing in the blood plasma.


Q: What happens if I forget to take Folvidon one day?

Official patient guidance indicates that a missed dose may be taken as soon as it is remembered. If the next scheduled dose is approaching, the guidance recommends skipping the missed dose and continuing with the regular schedule. It is advised not to take two doses at once.


Q: What is the official safety classification for Folvidon?

Folvidon’s active ingredient, Folic Acid, is officially classified as a vitamin and a hematopoietic agent (antianemic). It is also documented under Pregnancy Category A, which indicates that controlled studies in women have not shown a risk to the fetus.


Q: Are there any known interactions between Folvidon and common over-the-counter pain relievers?

Regulatory documents indicate no known interaction between Folic Acid and common over-the-counter pain relievers such as Paracetamol (Acetaminophen). Caution is advised, however, regarding the co-administration of Folic Acid with non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen if the patient is also taking Methotrexate.


Q: Is Folvidon a controlled substance?

According to regulatory classification systems, Folic Acid is listed as a vitamin. It is not scheduled or classified as a controlled substance in the United States.


Q: Is there a generic version of Folvidon available, or is it only brand name?

The active component of Folvidon is Folic Acid, which is widely available. Regulatory listings confirm that the active ingredient is available under various brand names as well as a generic product.


Q: Is Folvidon intended to be used with other treatments, or alone?

Official contraindications state that Folic Acid must not be used as the sole treatment for pernicious anemia or other megaloblastic anemias. This is because it can mask the blood-related signs of a Vitamin B12 deficiency while allowing serious neurological damage to progress.


Q: Does Folvidon have any known interactions with herbal products like St. John's Wort?

Official patient resources advise that patients consult a healthcare professional before using any herbal remedies or supplements alongside Folic Acid. This precautionary advice is given because certain supplements may contain Folic Acid or may affect its action in the body.


Q: Is it normal to feel a bit restless when first starting Folvidon?

Official product information lists 'overactivity' as a potential nervous system effect. This effect, which is related to restlessness, has been reported in association with prolonged administration of high doses, but it is not commonly listed as an expected side effect when first starting the medicine.

How should Folvidon be stored and disposed of?

Storage Conditions and Protection

Folvidon (Folic Acid) tablets must be stored at a Controlled Room Temperature, which is officially set between 20°C to 25°C (68°F to 77°F). Storage in environments where temperatures may exceed 30°C or where the product may freeze must be avoided.

Regulatory labeling requires that the tablets be protected from light and moisture. The product should remain in the original package and be stored in a well-closed container that is kept tightly closed.

Child Safety and Disposal

All medication must be stored out of the sight and reach of children. Unused or expired Folvidon must be disposed of safely and in accordance with local regulations. This often involves returning the product to a pharmacy or authorized collection point for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folvidon found in:

A-Z Index: